dna-20240507

0001628280-24-022896.txt : 20240513 0001628280-24-022896.hdr.sgml : 20240513 20240513161434 ACCESSION NUMBER: 0001628280-24-022896 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240507 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Ginkgo Bioworks Holdings, Inc. CENTRAL INDEX KEY: 0001830214 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 872652913 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40097 FILM NUMBER: 24939220 BUSINESS ADDRESS: STREET 1: 27 DRYDOCK AVENUE STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: (877) 442-5362 MAIL ADDRESS: STREET 1: 27 DRYDOCK AVENUE STREET 2: 8TH FLOOR CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Soaring Eagle Acquisition Corp. DATE OF NAME CHANGE: 20210210 FORMER COMPANY: FORMER CONFORMED NAME: Spinning Eagle Acquisition Corp. DATE OF NAME CHANGE: 20201027 8-K 1 dna-20240507.htm 8-K dna-20240507

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________________________________________________

FORM 8-K

______________________________________________________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 7, 2024

______________________________________________________________

GINKGO BIOWORKS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

______________________________________________________________

Delaware

001-40097

87-2652913

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

27 Drydock Avenue

8th Floor

Boston, MA 02210

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (877) 422-5362

(Former name or former address, if changed since last report)

______________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class

Trading
Symbol(s)

Name of each exchange
on which registered

Class A common stock, par value $0.0001 per share

DNA

NYSE

Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share

DNA.WS

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Requirement or Standard.

On May 7, 2024, Ginkgo Bioworks Holdings, Inc. (the “Company”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1.00 per share over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE.

Pursuant to Section 802.01C, the Company has a period of six months from receipt of the notice to regain compliance with the minimum stock price listing requirement. The Company may regain compliance at any time during the six-month cure period if on the last trading day of any calendar month during the six-month cure period the Company’s Class A common stock has a closing share price of at least $1.00 and an average closing share price of at least $1.00 over the 30 trading-day period ending on the last trading day of that month. If the Company is unable to regain compliance with the minimum share price requirement within the cure period, the NYSE will initiate procedures to suspend and delist the Company’s Class A common stock. The Company intends to regain compliance with NYSE's continued listing standards and is considering all available options to do so.

The Company will notify the NYSE within 10 business days of receipt of the notice of its intent to regain compliance with the requirements of Section 802.01C during the six-month cure period. The Company’s Class A common stock will continue to be listed and trade on the NYSE during this time under the trading symbol “DNA”, but will have an added designation of “.BC” to indicate that the Company is not currently in compliance with the NYSE’s continued listing standards.

Item 7.01. Regulation FD Disclosure.

As required by Section 802.01C of the NYSE Listed Company Manual, the Company issued a press release on May 13, 2024 announcing that it had received the notice of noncompliance with the NYSE’s continued listing standards. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated by reference to this Item 7.01.

The information in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing by Company under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language contained in such filing, unless otherwise expressly stated in such filing.

Forward-Looking Statements

Item 3.01 of this Current Report on Form 8-K contains certain forward-looking statements within the meaning of the federal securities laws, including statements related to the Company’s ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period, the Company’s ability to continue to comply with applicable listing standards of the NYSE, and any potential plans of the Company to cure the stock price deficiency. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this Current Report on Form 8-K, including but not limited to: (i) our ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period, (ii) our ability to continue to comply with applicable listing standards of the NYSE, (iii) volatility in the price of the Company’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting the Company’s business, (iv) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (v) the risk of downturns in demand for products using synthetic biology, (vi) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (viii) the outcome of any pending or potential legal proceedings against the Company, (ix) our ability to realize the expected benefits from and the success of our Foundry platform programs, (x) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (xi) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 29, 2024, the Company’s most recent quarterly report on Form 10-Q, and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those

contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.


Exhibit Number						Description

99.1						Press Release, issued by Ginkgo Bioworks Holdings, Inc. on May 13 , 2024

104						Cover Page Interactive Data File (embedded within the Inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	GINKGO BIOWORKS HOLDINGS, INC.

Date: May 13, 2024	By:	/s/ Mark Dmytruk
	Name:	Mark Dmytruk
	Title:	Chief Financial Officer

EX-99.1 2 ex991nysepr.htm EX-99.1 Document

Exhibit 99.1

Ginkgo Bioworks Receives Continued Listing Standard Notice From NYSE

Ginkgo’s Class A Common Stock continues to trade on the NYSE

BOSTON, Mass – May 13, 2024 – Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, “Ginkgo” or the “Company”), which is building the leading platform for cell programming and biosecurity, today announced that it received a notice on May 7, 2024 from the New York Stock Exchange (“NYSE”) informing the Company that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s Class A common stock was less than $1 per share over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s Class A common stock from the NYSE.

In accordance with applicable NYSE rules, the Company will notify the NYSE of its intent to regain compliance with applicable NYSE continued listing standards within 10 business days of receiving the notification. NYSE rules give Ginkgo a six-month period to regain compliance with the minimum price criteria. The Company intends to regain compliance with NYSE's continued listing standards and is considering all available options to do so.

Receipt of the NYSE notice does not affect Ginkgo’s business operations. The Company’s Class A common stock will continue to be listed and trade on the NYSE during the six-month cure period under the trading symbol “DNA”, but will have an added designation of “.BC” to indicate that the Company is not currently in compliance with the NYSE’s continued listing requirements.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo Biosecurity is building and deploying the next-generation infrastructure and technologies that global leaders need to predict, detect, and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and ginkgobiosecurity.com, read our blog, or follow us on social media channels such as X (@Ginkgo and @Ginkgo_Biosec), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

Forward-Looking Statements of Ginkgo Bioworks

This press release contains certain forward-looking statements within the meaning of the federal securities laws, including the Company’s ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period, the Company’s ability to continue to comply with applicable listing standards of the NYSE, and any potential plans of the Company to cure the stock price deficiency. These forward-looking statements generally are identified by the words “believe,” “can,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to regain compliance with the continued listing standards of the NYSE within the applicable cure period, (ii) our ability to continue to comply with applicable listing standards of the NYSE, (iii) volatility in the price of the Company’s securities due to a variety of factors, including changes in the competitive and highly regulated industries in which the Company operates and plans to operate, variations in performance across competitors, and changes in laws and regulations affecting the Company’s business, (iv) the ability to implement business plans, forecasts, and other expectations, and to identify and realize additional business opportunities, (v) the risk of downturns in demand for products using synthetic biology, (vi) the uncertainty regarding the demand for passive monitoring programs and biosecurity services, (vii) changes to the biosecurity industry, including due to advancements in technology, emerging competition and evolution in industry demands, standards and regulations, (viii) the outcome of any pending or potential legal proceedings against the Company, (ix)

our ability to realize the expected benefits from and the success of our Foundry platform programs, (x) our ability to successfully develop engineered cells, bioprocesses, data packages or other deliverables, and (xi) the product development or commercialization success of our customers. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s annual report on Form 10-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 29, 2024, the Company’s most recent quarterly report on Form 10-Q, and other documents filed by the Company from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. The Company does not give any assurance that it will achieve its expectations.

Ginkgo Bioworks Contacts:

INVESTOR CONTACT:

investors@ginkgobioworks.com

MEDIA CONTACT:

press@ginkgobioworks.com

EX-101.SCH 3 dna-20240507.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 dna-20240507_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 dna-20240507_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer Class of Stock [Domain] Class of Stock [Domain] Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Document Information [Line Items] Document Information [Line Items] Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share Warrant [Member] Class A common stock, par value $0.0001 per share Common Class A [Member] Document Type Document Type Amendment Flag Amendment Flag Class of Stock [Axis] Class of Stock [Axis] Document Information [Table] Document Information [Table] Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 6 dna-20240507_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover Page	May 07, 2024
Document Information [Line Items]
Document Type	8-K
Document Period End Date	May 07, 2024
Entity Registrant Name	GINKGO BIOWORKS HOLDINGS, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-40097
Entity Tax Identification Number	87-2652913
Entity Address, Address Line One	27 Drydock Avenue
Entity Address, Address Line Two	8th Floor
Entity Address, City or Town	Boston
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02210
City Area Code	877
Local Phone Number	422-5362
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false
Entity Central Index Key	0001830214
Amendment Flag	false
Class A common stock, par value $0.0001 per share
Document Information [Line Items]
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Trading Symbol	DNA
Security Exchange Name	NYSE
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol	DNA.WS
Security Exchange Name	NYSE

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 3 23 1 false 2 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.ginkgobioworks.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports dna-20240507.htm dna-20240507.xsd dna-20240507_def.xml dna-20240507_lab.xml dna-20240507_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "dna-20240507.htm": { "nsprefix": "dna", "nsuri": "http://www.ginkgobioworks.com/20240507", "dts": { "inline": { "local": [ "dna-20240507.htm" ] }, "schema": { "local": [ "dna-20240507.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "dna-20240507_def.xml" ] }, "labelLink": { "local": [ "dna-20240507_lab.xml" ] }, "presentationLink": { "local": [ "dna-20240507_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://www.ginkgobioworks.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dna-20240507.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "dna-20240507.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class A common stock, par value $0.0001 per share", "label": "Common Class A [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share", "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.ginkgobioworks.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001628280-24-022896-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-022896-xbrl.zip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end XML 18 dna-20240507_htm.xml IDEA: XBRL DOCUMENT 0001830214 2024-05-07 2024-05-07 0001830214 us-gaap:CommonClassAMember 2024-05-07 2024-05-07 0001830214 us-gaap:WarrantMember 2024-05-07 2024-05-07 0001830214 false 8-K 2024-05-07 GINKGO BIOWORKS HOLDINGS, INC. DE 001-40097 87-2652913 27 Drydock Avenue 8th Floor Boston MA 02210 877 422-5362 false false false false Class A common stock, par value $0.0001 per share DNA NYSE Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share DNA.WS NYSE false